The Vanderbilt Childhood Cancer Program is a collaboration of the
|
Special Expertise |
Highlight any special expertise physicians have at your institution, using bullets. Examples are as follows: · Bone marrow transplantation · Phase I clinical trials · Musculoskeletal tumors including sarcoma · Leukemias and lymphomas · Brain tumors
|
|---|
|
General Information |
615.936.1762 |
|---|---|
|
Referring Physician Line |
615.288.5000 |
|
Location |
|
|
Physical Plant |
Clinical care is delivered in the Monroe Carell Jr. Children's Hospital at Vanderbilt, a free-standing children's hospital opened in 2004 that includes a 12-unit self-contained HEPA-filtered wing that includes family gathering and patient play areas. |
|
Lodging |
Close relationship with the Ronald McDonald House, located just a few blocks from the hospital, and the American Cancer Society's Hope Lodge. |
|
Social Support |
Cancer patients and families have access to all of the support services of the Children's Hospital, including the The psychosocial team is composed of 3 social workers, 2 child life specialists, 3 child psychologists and the Children's Hospital chaplain. The members of this team meet on a regular basis, together with the Pediatric Advanced Care Team ( |
|
Home Health Care |
Vanderbilt Children's Home Care Program offers a variety of home care services catering to the individual needs of patients; we provide both intermittent and private duty services. The quality and level of care is in complete agreement with Children's Hospital standards, ensuring safe and effective treatment with all the benefits of home. As an affiliate of
Patient and Family Education-Pediatric home care nurses and rehabilitation therapists provide initial assessment, home care instruction and ongoing visit support. We assist our patients and families to overcome their fears and concerns about being at home. Working with the hospital staff, we aid the discharge process before the patient arrives home. All of these efforts are done with one goal in mind: a positive outcome for the patient and their family |
|
Ages Treated |
0-21 |
|
Director, Vanderbilt Childhood Cancer Program |
James Whitlock, MD, Director of Pediatric Hematology-Oncology and Craig Weaver Professor of Pediatrics. |
|---|---|
|
Multidisciplinary Teams |
A multidisciplinary team of the following specialists addresses the complex needs of young patients and their families before, during, and after treatment: · physicians; · clinical nurse specialists; · psychologists; · pharmacists; · clinical social workers; · dietitians; · physical, occupational, art, and recreation therapists; · child life specialists; · school reintegration coordinators; and · case managers Weekly tumor conferences are held. |
|
Cooperative Group Membership |
Children's Oncology Group ( Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC ) Pediatric Blood and Marrow Transplant Consortium Sarcoma |
|
Activities in Cooperative Group |
Leadership and participation in clinical trials |
|
Average Number of Pediatric Clinical Trials |
Highlights of childhood cancer research faculty:
Dr. Whitlock's research interest include the biology and treatment of acute lymphocytic leukemia and acute nonlymphocytic leukemia, the biology and treatment of Langerhans cell histiocytosis and other forms of histiocytosis, and the development of new agents for the treatment of childhood cancers and blood diseases. He is actively involved in clinical research in these areas and has leadership roles in the Children's Oncology Group (
Richard Ho, MD: identification and functional characterization of naturally occurring polymorphisms in drug transport proteins as they relate to drug disposition. To this extent, we focus on pharmacogenetics, the study of the role of inheritance in the individual variation in drug response. Even though individual differences in drug response can result from the effects of age, sex, disease, or drug interactions, genetic factors also influence both the efficacy of a drug and the likelihood of an adverse reaction. Transport proteins have an important role in regulating the absorption, distribution, and excretion of many medications as well as endogenous substances. Dr. Ho is currently studying several transport proteins important to the disposition of a number of chemotherapeutics agents and include such transporters as the multidrug resistance associated proteins (MRPs), the bile salt export pump (BSEP), and the breast cancer related protein (BCRP). Projects are primarily laboratory based and rely on background knowledge in the fields of molecular biology and pharmacology.
John F. Kuttesch Jr., PhD, MD: development and evaluation of new therapies for childhood brain tumors, including targeted molecular therapies to be used alone or in combination with other approaches.
Anderson B. Collier, MD: determining genetic factors that affect cancer development in children and improving supportive care for children and adolescents receiving chemotherapy for cancer.
Jennifer A. Domm, MD: pediatric hemostasis and thrombosis
Michael Engel, MD, PhD: molecular mechanisms of hematopoiesis and leukemogenesis, cellular signal transduction, biochemistry and identification of novel therapeutic for myeloid and lymphoid leukemias.
Pediatric Stem Cell Transplant Program
Led by Haydar Frangoul, MD and staffed by three attending physicians, a pediatric nurse practitioner, a nurse coordinator, and a clinical pharmacist, this program provides comprehensive transplantation services, including unrelated donor and cord blood transplants, for children and adolescents with malignant and non-malignant disorders. A 12-bed HEPA-filtered stem cell transplant unit is located within the Children's Hospital. The program is an active participant in the National Marrow Donor Program and the Pediatric Blood & Marrow Transplant Consortium. The Pediatric Stem Cell Transplant Program is approved by the National Marrow Donor Program, the Bone Marrow Transplant Committee of
Pediatric Cancer Experimental Therapies Program
Led by James Whitlock, MD, Vanderbilt participates in clinical trials of novel agents through POETIC (Pediatric Oncology Experimental Therapeutics Investigators' Consortium) which also includes childhood cancer programs at M.D. Anderson, Memorial Sloan-Kettering Cancer Center, the Sidney Kimmel Cancer Center at Johns Hopkins, Children's Healthcare of Atlanta at Egleston, the Children's Hospital at the University of Colorado the University of Florida, and the University of Arizona, and SARC. This program is funded in part by an infrastructure grant from the Alex's Lemonade Stand Foundation.
Pediatric Brain Tumor Program
Led by John Kuttesch, PhD, MD, this program provides multi-disciplinary care for children with tumors of the primary central nervous system. Treatment programs are developed in collaboration with other members of the
Childhood Cancer Survivorship Program
This program provides a full range of follow-up care designed to meet the unique health care needs of each survivor. The program provides care based on recommendations from the Children's Oncology Group (www.survivorshipguidelines.org).The team consists of oncologists, pediatricians, internists, endocrinologists, psychologists, and a nurse coordinator. In addition to the evaluations provided by the survivorship clinic, referrals can be made for evaluations in other specialty clinics such as Pulmonology, Ophthalmology, or Cardiology. Our program is an invited member of the COG's Survivorship / Cancer Control Consortium.
Adolescent and Young Adult Cancer Program
Led by Anderson Collier, MD, the program is working with the
|
No. of Inpatient Beds |
No. of Admissions |
Total Outpatient Visits |
No. of Bone Marrow Transplants |
No. of Oncologists |
|---|---|---|---|---|
|
12-bed HEPA filtered myelosuppression unit plus 12 oncology beds |
1050 in FY 2007 |
14,800 in FY 2007 |
29 in FY 2007 |
10 |
Privacy Policy| Legal Notices| Site Map| Contact Us| Help
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved